Most Read Articles
3 days ago
Ivermectin confers benefits in the treatment of COVID-19, with a recent study showing that its use helps reduce the risk of death especially in patients with severe pulmonary involvement.
2 days ago
Mental health comorbidities are common among patients with type 2 diabetes mellitus and may lead to worse outcomes, a recent study has found.
Roshini Claire Anthony, 13 Nov 2020

Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.

Tristan Manalac, 6 days ago
The substitution of isoleucine to leucine at amino acid 97 (I97L) in the core region of the hepatitis B virus (HBV) seems to reduce its potency, decreasing the efficiency of both infection and the synthesis of the virus’ covalently closed circular (ccc) DNA, reports a new study presented at The Liver Meeting Digital Experience by the American Association for the Study of Liver Diseases (AASLD 2020).

Integrate genetic testing into local routine oncology care

Dr Joslyn Ngu
04 Dec 2017

Identification of BRCA mutation in ovarian cancer is vital because it allows better risk management and there is evidence that carriers may benefit from new treatment modalities, said Professor Woo Yin Ling, consultant gynaecological oncologist at the University of Malaya.

Locally, 12 percent of ovarian cancer patients are carriers of a germline BRCA1 or BRCA2 mutations. Genetic counselling plays a crucial role in cancer genetics; interpretation of the results of genetic testing is unique to every individual and her situation, she explained. Unfortunately, there are several barriers to overcome, such as lack of population-based data on genetic mutation in Asians, lack of access to BRCA testing, lack of awareness among healthcare professionals, complex interpretation of genetic test results and psychosocial barriers.

Together with Cancer Research Malaysia, Woo and other healthcare professionals are conducting the MaGiC (MAinstreaming GenetIc Counselling for genetic testing of BRCA1 and BRCA2 in ovarian cancer patients in Malaysia) trial as part of an effort to make genetic counselling mainstream in the country. The study aims to establish a local population-based cohort of ovarian cancer patients to determine the prevalence of mutations, feasibility of mainstreaming BRCA1 and BRCA2 testing for ovarian cancer and psychosocial impact of genetic testing.

Preliminary findings showed the identification of 20 new BRCA carriers from different states in Malaysia. Previously, identified BRCA carriers were mostly from Klang Valley. With the identification of carriers outside of Klang Valley, risk management protocols were then set up in those hospitals and training is provided for clinicians to form multidisciplinary teams for risk management, said Woo. Another preliminary finding is that majority of patients felt counselling done by their doctors were valuable; indicating the importance of physician-led genetic counselling.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
3 days ago
Ivermectin confers benefits in the treatment of COVID-19, with a recent study showing that its use helps reduce the risk of death especially in patients with severe pulmonary involvement.
2 days ago
Mental health comorbidities are common among patients with type 2 diabetes mellitus and may lead to worse outcomes, a recent study has found.
Roshini Claire Anthony, 13 Nov 2020

Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.

Tristan Manalac, 6 days ago
The substitution of isoleucine to leucine at amino acid 97 (I97L) in the core region of the hepatitis B virus (HBV) seems to reduce its potency, decreasing the efficiency of both infection and the synthesis of the virus’ covalently closed circular (ccc) DNA, reports a new study presented at The Liver Meeting Digital Experience by the American Association for the Study of Liver Diseases (AASLD 2020).